Haijia Medical Holdings Limited (Stock Code: 06078) submitted the next day disclosure report on September 11, 2024, disclosing the changes in its issued shares or treasury shares. The report shows that from September 2 to September 11, 2024, the company repurchased shares in accordance with the regulations of the Hong Kong Stock Exchange and intends to cancel the related shares. The total number of repurchased shares is 4,123,400 shares, accounting for 0.6529% of the issued shares. The repurchase price range is HKD 15.18 to HKD 18.2396. The company confirms that all repurchase activities have obtained formal approval from the board of directors and comply with relevant listing rules and laws regulations. After the repurchase activities, the company will enter a one-month moratorium period until October 11, 2024, during which no new shares may be issued or any treasury shares may be sold or transferred.

Haijia Medical Holdings Limited (Stock Code: 06078) submitted the next day disclosure report on September 11, 2024, disclosing the changes in its issued shares or treasury shares. The report shows that from September 2 to September 11, 2024, the company repurchased shares in accordance with the regulations of the Hong Kong Stock Exchange and intends to cancel the related shares. The total number of repurchased shares is 4,123,400 shares, accounting for 0.6529% of the issued shares. The repurchase price range is HKD 15.18 to HKD 18.2396. The company confirms that all repurchase activities have obtained formal approval from the board of directors and comply with relevant listing rules and laws regulations. After the repurchase activities, the company will enter a one-month moratorium period until October 11, 2024, during which no new shares may be issued or any treasury shares may be sold or transferred.